J. Beaver

Population pharmacokinetics of TC‐5214, a nicotinic channel modulator, in phase I and II clinical studies

S. Toler, Hongmei Xu, N. Al-Huniti, 2014, Journal of clinical pharmacology.

Phase 2 Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) in Negative and Cognitive Symptoms of Schizophrenia.

G. Dunbar, S. Marder, J. Kane, 2016, Schizophrenia bulletin.

Pharmacokinetics and pharmacodynamics of six epoetin alfa dosing regimens in anemic critically ill patients without acute blood loss*

A. Arroliga, K. Kelly, W. Langholff, 2009, Critical care medicine.

TC‐5214 (S‐(+)‐Mecamylamine): A Neuronal Nicotinic Receptor Modulator with Antidepressant Activity

Jianxun Xie, M. Bencherif, G. Gatto, 2008, CNS neuroscience & therapeutics.

A Randomized Exploratory Trial of an Alpha-7 Nicotinic Receptor Agonist (TC-5619) for Cognitive Enhancement in Schizophrenia

J. Lieberman, N. Duan, G. Dunbar, 2013, Neuropsychopharmacology.

Pharmacokinetic and pharmacodynamic profiles of extended dosing of epoetin alfa in anemic patients who have chronic kidney disease and are not on dialysis.

N. Vaccaro, J. Massarella, T. McGowan, 2008, Clinical journal of the American Society of Nephrology : CJASN.

Pharmacokinetics and pharmacodynamics of once-weekly subcutaneous epoetin alfa in critically ill patients: Results of a randomized, double-blind, placebo-controlled trial*

J. Vincent, I. Hubloue, H. Spapen, 2006, Critical care medicine.